Story perspectives

Judge Blocks FDA Mail-Order Mifepristone Rule, Sparks Midterm Debate

5/3/2026

Summary

Story summary

A federal judge struck down the FDA’s 2023 mail-order mifepristone rule, reversing the 5th Circuit’s in-person rule, Danco Laboratories’ stay petition, and Louisiana Attorney General Liz Murrill’s lawsuit that Judge Kyle Duncan endorsed.
Republican officials and anti-abortion groups praised the ruling, while Planned Parenthood called it a setback.
The decision is expected to dominate the 2026 midterm race after voters backed abortion rights in 14 of 17 state ballot measures.

History

Historical Context

The Supreme Court’s 1992 Casey decision, a 5-4 ruling authored by Justice Sandra Day O’Connor, reaffirmed Roe v. Wade while creating the “undue burden” test that lets states impose waiting periods and counseling. That framework, together with the FDA’s 2000 approval of mifepristone, underpinned Judge Kyle Duncan’s 2024 ruling that struck down the agency’s mail-order rule, reigniting abortion-access battles.

1 of 2

Story summary

A federal judge struck down the FDA’s 2023 mail-order mifepristone rule, reversing the 5th Circuit’s in-person rule, Danco Laboratories’ stay petition, and Louisiana Attorney General Liz Murrill’s lawsuit that Judge Kyle Duncan endorsed.
Republican officials and anti-abortion groups praised the ruling, while Planned Parenthood called it a setback.
The decision is expected to dominate the 2026 midterm race after voters backed abortion rights in 14 of 17 state ballot measures.

1 / 2